Logo
x

Search category

Subscribe Now

Genomic Tumor Aberrations

Genentech's Tecentriq Receives FDA Approval a Combination Therapy- for mNon-Sq NSCLC with No EGFR or ALK Genomic Tumor Aberrations

Genentech's Tecentriq Receives FDA Approval a Combination Therapy- for mNon-Sq NSCLC with No EGFR or ALK Genomic Tumor Aberrations

  • December 7, 2018
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.